US Pharma MarketingJ&J’s Imaavy secures expanded US approval in rare blood disorder
J&J’s Imaavy secures expanded US approval in rare blood disorder is a pharma and life sciences industry update from Pharmaceutical Technology. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
The FDA approval marks another successful step in J&J’s aim of achieving $5bn in peak sales for the drug.
Source: Pharmaceutical Technology